{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"0.0","upperLimit":"0.0","value":"0.00"},{"groupId":"OG001","lowerLimit":"0.0","upperLimit":"0.0","value":"0.00"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"33"},{"groupId":"OG001","value":"37"}],"units":"Participants"}],"title":"CYCLE 1 DAY 1, PRE-DOSE"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"0.0","upperLimit":"550.0","value":"143.00"},{"groupId":"OG001","lowerLimit":"0.0","upperLimit":"1360.0","value":"453.00"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"34"},{"groupId":"OG001","value":"35"}],"units":"Participants"}],"title":"CYCLE 1 DAY 1, END OF INFUSION"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"69.3","upperLimit":"675.0","value":"179.00"},{"groupId":"OG001","lowerLimit":"175.0","upperLimit":"2590.0","value":"513.00"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"33"},{"groupId":"OG001","value":"35"}],"units":"Participants"}],"title":"CYCLE 1 DAY 1, 2 HOURS"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"137.0","upperLimit":"4960.0","value":"291.00"},{"groupId":"OG001","lowerLimit":"436.0","upperLimit":"5970.0","value":"778.00"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"31"},{"groupId":"OG001","value":"32"}],"units":"Participants"}],"title":"CYCLE 1 DAY 1, 24 HOURS"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"98.5","upperLimit":"1470.0","value":"237.00"},{"groupId":"OG001","lowerLimit":"235.0","upperLimit":"2530.0","value":"548.00"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"33"},{"groupId":"OG001","value":"36"}],"units":"Participants"}],"title":"CYCLE 1 DAY 4, ANYTIME SAMPLE"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"0.0","upperLimit":"629.0","value":"61.20"},{"groupId":"OG001","lowerLimit":"81.9","upperLimit":"548.0","value":"200.00"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"32"},{"groupId":"OG001","value":"35"}],"units":"Participants"}],"title":"CYCLE 1 DAY 8, ANYTIME SAMPLE"},{"categories":[{"measurements":[{"comment":"Full range is not applicable as only a single participant was analyzed. Median value presented here is the actual concentration for this single participant.","groupId":"OG000","lowerLimit":"NA","upperLimit":"NA","value":"0.00"},{"groupId":"OG001","lowerLimit":"0.0","upperLimit":"0.0","value":"0.00"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"5"}],"units":"Participants"}],"title":"CYCLE 1 DAY 22, ANYTIME SAMPLE"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"0.0","upperLimit":"94.2","value":"0.00"},{"groupId":"OG001","lowerLimit":"0.0","upperLimit":"55.0","value":"0.00"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"28"},{"groupId":"OG001","value":"31"}],"units":"Participants"}],"title":"CYCLE 2 DAY 1, PRE-DOSE"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"0.0","upperLimit":"698.0","value":"126.00"},{"groupId":"OG001","lowerLimit":"0.0","upperLimit":"684.0","value":"329.00"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"28"},{"groupId":"OG001","value":"31"}],"units":"Participants"}],"title":"CYCLE 2 DAY 1, END OF INFUSION"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"0.0","upperLimit":"0.0","value":"0.00"},{"groupId":"OG001","lowerLimit":"0.0","upperLimit":"0.0","value":"0.00"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"22"},{"groupId":"OG001","value":"17"}],"units":"Participants"}],"title":"CYCLE 4 DAY 1, PRE-DOSE"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"0.0","upperLimit":"293.0","value":"128.50"},{"groupId":"OG001","lowerLimit":"119.0","upperLimit":"987.0","value":"351.50"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"22"},{"groupId":"OG001","value":"16"}],"units":"Participants"}],"title":"CYCLE 4 DAY 1, END OF INFUSION"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"0.0","upperLimit":"0.0","value":"0.00"},{"groupId":"OG001","lowerLimit":"0.0","upperLimit":"115.0","value":"0.00"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"13"},{"groupId":"OG001","value":"13"}],"units":"Participants"}],"title":"CYCLE 6 DAY 1, PRE-DOSE"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"54.4","upperLimit":"199.0","value":"113.00"},{"groupId":"OG001","lowerLimit":"0.0","upperLimit":"492.0","value":"213.00"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"13"},{"groupId":"OG001","value":"13"}],"units":"Participants"}],"title":"CYCLE 6 DAY 1, END OF INFUSION"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"0.0","upperLimit":"0.0","value":"0.00"},{"groupId":"OG001","lowerLimit":"0.0","upperLimit":"0.0","value":"0.00"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"5"},{"groupId":"OG001","value":"9"}],"units":"Participants"}],"title":"CYCLE 9 DAY 1, PRE-DOSE"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"59.6","upperLimit":"179.0","value":"137.00"},{"groupId":"OG001","lowerLimit":"0.0","upperLimit":"533.0","value":"172.00"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"5"},{"groupId":"OG001","value":"9"}],"units":"Participants"}],"title":"CYCLE 9 DAY 1, END OF INFUSION"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"0.0","upperLimit":"0.0","value":"0.00"},{"groupId":"OG001","lowerLimit":"0.0","upperLimit":"52.5","value":"0.00"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"5"},{"groupId":"OG001","value":"8"}],"units":"Participants"}],"title":"CYCLE 12 DAY 1, PRE-DOSE"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"71.1","upperLimit":"210.0","value":"112.00"},{"groupId":"OG001","lowerLimit":"0.0","upperLimit":"2120.0","value":"261.00"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"5"},{"groupId":"OG001","value":"7"}],"units":"Participants"}],"title":"CYCLE 12 DAY 1, END OF INFUSION"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"0.0","upperLimit":"0.0","value":"0.00"},{"groupId":"OG001","lowerLimit":"0.0","upperLimit":"0.0","value":"0.00"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"4"},{"groupId":"OG001","value":"6"}],"units":"Participants"}],"title":"CYCLE 18 DAY 1, PRE-DOSE"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"0.0","upperLimit":"276.0","value":"0.00"},{"groupId":"OG001","lowerLimit":"0.0","upperLimit":"162.0","value":"0.00"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"26"},{"groupId":"OG001","value":"20"}],"units":"Participants"}],"title":"END OF TREATMENT (~157 weeks)"}],"denoms":[{"counts":[{"groupId":"OG000","value":"34"},{"groupId":"OG001","value":"37"}],"units":"Participants"}],"description":"Blood samples were collected for PK analysis of belantamab mafodotin cys- monomethyl auristatin-F (cys-mcMMAF).","dispersionType":"Full Range","groups":[{"description":"In CE Phase, Participants with RRMM received 0.95 mg/ kg belantamab mafodotin IV infusion as powder for solution once every 3 weeks (Q3W), infused over 30- 60 minutes on day 1 of 21-day cycles in combination with 100 mg nirogacestat BID on day 1, 4, 8 and 15 of 21-day cycles. Treatment was administered until disease progression, intolerable toxicity, informed consent withdrawal, the end of the sub-study or death.","id":"OG000","title":"CE Phase: 0.95mg/kg Belantamab Mafodotin Q3W + Nirogacestat"},{"description":"In CE Phase, Participants with RRMM received 2.5 mg/ kg belantamab mafodotin IV infusion as powder for solution Q3W, infused over 30- 60 minutes on day 1 of 21-day cycles until disease progression, intolerable toxicity, informed consent withdrawal, the end of the sub-study or death.","id":"OG001","title":"CE Phase: 2.5mg/kg Belantamab Mafodotin Q3W"}],"paramType":"MEDIAN","populationDescription":"Pharmacokinetic population. Only those participants who were measured and analyzed (i.e., contributed data reported in the table) were included in the Overall Number of Participants Analyzed field. 'Number Analyzed' signifies participants evaluable for the specified timepoints.","reportingStatus":"POSTED","timeFrame":"PRE-DOSE(PD), END OF INFUSION (EOI), EOI+2 HOURS(H), EOI+ 24H on Day(D) 1 of Cycle (C) 1; ANYTIME on C1 D4, D8, D22 ; PD and EOI on D1 of C2, C4, C6, C9, C12; PD on D1 of C18; End of Treatment (approximately 157 weeks)","title":"CE Phase: Plasma Concentrations of Belantamab Mafodotin Cys- Monomethyl Auristatin-F (Cys-mcMMAF)","type":"SECONDARY","unitOfMeasure":"pg/mL"}